pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
MODALITY
save

Bispecific Antibody

Antibody binding two targets simultaneously.

also known as: bsab, bispecific
drugs
0
catalysts
0
news
664
companies
0

Top drugs

no drugs tagged with this interest yet

🐶 Top companies

no companies tagged with this interest yet

Recent catalysts

no catalysts tagged with this interest yet

Recent news

view all →
  • AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal↗
    biospace · 3d ago
  • Ramping up: 3 biotechs growing their workforce after series C raises↗
    biospace · 3d ago
  • AbbVie busts a move with Disco in $2.5B dance aimed at bispecific discovery↗
    fiercebiotech · 4d ago
  • Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight↗
    biospace · 4d ago
  • 5 acquisitions that forced Big Pharmas to co-parent↗
    biospace · 4d ago
  • FDA letter rejecting Summit cancer drug cites ‘modest’ benefit in data compared with toxicity risk↗
    endpoints · 5d ago
  • FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival miss↗
    fiercebiotech · 5d ago
  • Summit shares fall as FDA rejects closely watched PD-1/VEGF drug↗
    biopharma dive · 6d ago
Data sources
openFDA · ClinicalTrials.gov · pharmadog Linker
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?